A Phase 4 interventional study of Metformin in Polycystic Ovary Syndrome, sponsored by Biocinese. Status unknown at 1 site in Brazil. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2011-06-06.
Sponsored by Biocinese · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies testing metformin in Polycystic Ovary Syndrome — 9 open to participants now, 11 under way, 3 of them phase 3. Metformin · Polycystic Ovary Syndrome.
Among the 114 studies testing metformin in Polycystic Ovary Syndrome, this one is the 99th largest by planned enrollment of the 113 interventional ones that give a count, is one of 7 that started in 2011, is one of 33 in phase 4, and was the 34th registered.
958 studies on the registry are indexed under Polycystic Ovary Syndrome; 175 are open to participants now.
Browse Polycystic Ovary Syndrome studies →9 of the 114 studies testing metformin in Polycystic Ovary Syndrome are open now, in 11 countries. Recruiting first, the newest first:
Dicle University · Sites in Turkey
Ages 20–40 · Women only
Peking University Third Hospital · Sites in China
Ages 20–40 · Women only
Future University in Egypt · Sites in Egypt
Ages 18–40 · Women only
Shanghai 10th People's Hospital · Sites in China
Ages 18–45 · Women only
Fundació Sant Joan de Déu · Sites in Austria, Denmark, Italy and 3 more countries
Ages 12–23 · Women only
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 119 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 105 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 13 · Phase 3 21 · Phase 4 33
First in 1997; this study’s year is marked. 7 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 70 across 699 interventional studies indexed under Polycystic Ovary Syndrome.
Median enrollment 75 across the 113 interventional studies. Of the 78 that completed or were terminated, 12 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 114 have an industry lead sponsor. The 10 most frequent:
Biocinese is the lead sponsor of 3 studies on the registry; none are open to participants now.
Biocinese has 1 study filed under Polycystic Ovary Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies testing metformin in Polycystic Ovary Syndrome that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07604779Beni-Suef UniversityEnhancing PCOS Management for Better Outcomes of Intracytoplasmic Sperm Injection | 2026-12-03 |
| NCT05680805Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshMetabolic Responses of Metformin and Genetic Polymorphisms of SLC22A1 Gene in PCOS | 2026-12-30 |
| NCT07770711Dicle UniversityInositol and Metformin Administration in Mediterranean Diet and Low-Carbohydrate Diets in Women With PCOS | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 114 studies testing metformin in Polycystic Ovary Syndrome, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Metformin is one of the most commonly prescribed drugs worldwide for the treatment of Type 2 Diabetes. It has been currently used for the treatment of: polycystic ovary syndrome, gestational diabetes, metabolic syndrome and obesity. In patients with polycystic ovary syndrome (PCOS) the adverse side effects are a frequent cause for treatment discontinuation. In every day medical practice lower doses of Metformin are administered searching for the continuation of the treatment.
However, there is no clinical study to support this assertion. The objective of this study is to monitor and correlate the therapeutic effect of Metformin on patients with PCOS taking daily doses of 1500mg and 1000mg.
Patients with PCOS diagnosis and that are able to attempt the inclusion criteria are divided in two groups: administration of metformin 500 mg tablet three times/day as well 1500 mg/day (group A)and administration of metformin 500 mg tablet twice/day or 1000 mg/day (group B). Blood samples were collected to the pharmacokinetic evaluation from first day of administration until 3 months after beginning of treatment. The patients are monitored during 3 months and all side effects are register. The efficacy of both treatment are analyzed by biochemical and physical evaluation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
study parallel with one arm only.
Drug: Metformin
Metformin 500 mg tablet (1000 or 1500 mg/day)
Also known as: Glifage 500 mg
Plasma concentration of metformin
Blood samples are collected from each patient and the plasma concentration is analysed.
Time frame: First day after administration until 3 months after begining of treatment
Number of adverse events
All adverse events are registered during the treatment
Time frame: observation during 3 months of treatment
The record gives a start of Jan 2011, a primary completion of Aug 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin